Trial Profile
A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Favezelimab (Primary) ; Pembrolizumab (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Hodgkin's disease; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 12 Dec 2023 Results (n=25) from cohort 3 presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results (n=34 from Cohort 2) assessing safety and efficacy of Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti PD-1 Refractory Classical Hodgkin Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results( cutoff(March 2, 2023)) presented at the 65th American Society of Hematology Annual Meeting and Exposition